Fact ✅️: I cited THREE independently peer-reviewed papers specific to only the DCVax®-L platform technology alone… There are other recent peer-reviewed papers relevant to dendritic cell platforms too, & all DC research is relevant to the development of the field overall…
Intratumoral delivery of dendritic cells combined with anti-HER2 antibodies is safe and effective in altering the tumor microenvironment and inducing dramatic tumor regression prior to chemotherapy in early-stage HER2-positive breast cancer. https://t.co/QgI6ZQfgtqpic.twitter.com/kLMjIDjwXj